TAM Receptor

Receptor

Tyro3; Axl; Mer

TAM Receptor Isoform Specific Products:

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-146596

Axl-IN-5	Inhibitor
Axl-IN-5 (compound 1) is a AXL inhibitor with an IC₅₀ of 283 nM. Axl-IN-5 has anticancer effects.

HY-12965B

(Z)-S49076 hydrochloride	Inhibitor
(Z)-S49076 hydrochloride is an orally active inhibitor of MET and AXL that blocks the downstream signaling of these receptors both in vitro and in vivo, inhibiting the proliferation and migration of tumor cells and suppressing tumor growth in xenograft models. (Z)-S49076 hydrochloride is capable of overcoming the resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) due to MET amplification in Erlotinib (HY-50896)-resistant cell lines both in vitro and in vivo. (Z)-S49076 hydrochloride can be used for research in non-small cell lung cancer (NSCLC).

HY-145622

Mecbotamab vedotin	Inhibitor
Mecbotamab vedotin (BA301) is an IgG1 antibody inhibitor of anti-(human tyrosine kinase receptor AXL) (human-Mus musculus monoclonal BA301 γ1-chain). Mecbotamab vedotin can be used to make immunoconjugates for Methods of Axl-expressing cancers research.

HY-169517

Protein kinase inhibitor 10	Inhibitor
Protein kinase inhibitor 10 is a protein kinase inhibitor with IC₅₀ values of 28.9, 13.6, and 2.41 μM for TAM receptor, FAK, and KIT, respectively. Protein kinase inhibitor 10 can inhibit abnormal and excessive cell proliferation, showing promise for research in cancer therapy.

HY-W400801

Denfivontinib hydrochloride	Inhibitor
Denfivontinib (G-749) hydrochloride is an AXL inhibitor that has synergistic antitumor effects with the PD-1 inhibitor Pembrolizumab (HY-P9902). Denfivontinib can enhance the NOD-like receptor pathway, thereby promoting the formation of the NLRP3 inflammasome.

HY-164382

ER-851	Inhibitor
ER-851 is a selective AXL inhibitor with oral activity with IC₅₀ of 100 nM. ER-851 has antitumor activity.

Bemcentinib	Axl			99.92%
Gilteritinib	Axl			99.84%
Cabozantinib	Axl			99.96%
2-D08	Axl			99.17%
LDC1267	Axl	Mer	Tyro3	99.64%
UNC9426	Axl, IC₅₀: 190 nM	MERTK, IC₅₀: 580 nM	Tyro3, IC₅₀: 2.1 nM
UNC8212	Axl, IC₅₀: 1.3 nM	MERTK, IC₅₀: 1.5 nM	Tyro3, IC₅₀: 6.7 nM
Dubermatinib	Axl			99.84%
BMS 777607	Axl		Tyro3	99.36%
UNC2250	Axl	Mer		99.92%
Zanzalintinib	Axl	Mer		99.91%
Gilteritinib hemifumarate	Axl			99.75%
UNC2541		Mer		99.71%
UNC569	Axl	Mer	Tyro3	99.92%
Tamnorzatinib	Axl	Mer	Tyro3	98.07%
UNC5293	Axl		Tyro3	99.93%
Batiraxcept	Axl			99.91%
CEP-40783	Axl			99.12%
UNC1062	Axl		Tyro3	99.48%
SGI-7079	Axl			99.32%
Tilvestamab	Axl			98.08%
Ningetinib	Axl			99.82%
UNC2881	Axl	Mer		99.79%
Enapotamab	Axl			≥99.0%
NPS-1034	Axl			≥98.0%
RU-302	Axl			98.72%
Cabozantinib-d₆	Axl			98.14%
UNC4203	Axl		Tyro3	99.80%
DS-1205b free base	Axl	Mer		99.92%
PROTAC Axl Degrader 2	Axl			98.01%
AXL-IN-13	Axl			98.03%
Mipasetamab	Axl			98.26%
Ningetinib Tosylate	Axl			99.59%
Mecbotamab	Axl			99.10%
TL4830031	Axl			≥98.0%
PF-07265807	Axl	Mer	Tyro3
AZ14145845	Axl	Mer
Cabozantinib hydrochloride	Axl
Axl-IN-6	Axl
Axl-IN-9	Axl
Axl-IN-11	Axl
PROTAC Axl Degrader 1	Axl
Axl-IN-4	Axl
Axl-IN-17	Axl, IC₅₀: 3.23 nM	Mer	Tyro3
Axl-IN-10	Axl
Bemcentinib (GMP)	Axl
HIV-IN-7	Axl
Axl/Mer/CSF1R-IN-1	Axl	Mer
Axl-IN-12	Axl
AXL-IN-15	Axl
Axl-IN-7	Axl
Axl-IN-16	Axl
Axl-IN-8	Axl
Anticancer agent 109	Axl
Axl-IN-3	Axl
R916562	Axl
AXL-IN-14	Axl
Axl-IN-5	Axl

Name
Email *

	Sorry, but the email address you supplied was invalid.